{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-281920","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.006828+00:00","generated_at":"2026-06-21T23:20:47.047479+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cabaletta Bio Q3 2022: cash $85.9M; CABA-201 IND submission planned 1H 2023; MuSK-CAART ODD granted","bullets":["Q3 2022 R&D expenses $8.2M, G&A $3.6M; cash and investments $85.9M, down from $122.2M at Dec 31, 2021.","Obtained exclusive worldwide license from IASO Bio for CD19 binder used in CABA-201, a fully human CD19-CAR T candidate; IND submission planned 1H 2023.","FDA granted Orphan Drug Designation to MuSK-CAART for MuSK- myasthenia gravis; first-in-human trial initiation expected Q4 2022.","Updated DesCAARTes interim data shows favorable safety; combination cohort (DSG3-CAART + IVIg/cyclophosphamide) 1-month data expected Q1 2023.","Cash runway through Q2 2024; initial CABA-201 clinical data expected by 1H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-281920","json":"https://secwatch.observer/filing/0001193125-22-281920.json","markdown":"https://secwatch.observer/filing/0001193125-22-281920.md","text":"https://secwatch.observer/filing/0001193125-22-281920.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000119312522281920/0001193125-22-281920-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000119312522281920/d397150d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:20:47.047479+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"14b81e0726918a2b834058c6d87663b4b3bcb34f","claim":"Cabaletta Bio, Inc. reported financial results for third quarter ended September 30, 2022.","evidence_excerpt":"On November 10, 2022, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000119312522281920/0001193125-22-281920-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}